Last reviewed · How we verify
Vehicle Ophthalmic Solution QID
Vehicle Ophthalmic Solution QID is a carrier solution used in clinical trials to deliver active drugs to the eye, without having a direct therapeutic effect itself.
Vehicle Ophthalmic Solution QID is a carrier solution used in clinical trials to deliver active drugs to the eye, without having a direct therapeutic effect itself. Used for Used as a control in clinical trials for ophthalmic conditions.
At a glance
| Generic name | Vehicle Ophthalmic Solution QID |
|---|---|
| Sponsor | Aldeyra Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It serves as a control in clinical studies to help differentiate the effects of the active drug from the placebo. The solution is designed to mimic the physical properties of potential active treatments without containing any active pharmaceutical ingredients.
Approved indications
- Used as a control in clinical trials for ophthalmic conditions
Common side effects
- Eye irritation
- Conjunctival hyperemia
Key clinical trials
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers (PHASE1)
- A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye (PHASE3)
- A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease (PHASE3)
- A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease (PHASE3)
- A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (PHASE2)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients (PHASE2)
- A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |